Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease
Ollech J, Normatov I, Peleg N, Wang J, Patel S, Rai V, Yi Y, Singer J, Dalal S, Sakuraba A, Cohen R, Rubin D, Pekow J. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease. Clinical Gastroenterology And Hepatology 2020, 19: 104-110. PMID: 32109634, PMCID: PMC8665415, DOI: 10.1016/j.cgh.2020.02.035.Peer-Reviewed Original ResearchMeSH KeywordsC-Reactive ProteinCrohn DiseaseHumansLeukocyte L1 Antigen ComplexRemission InductionRetrospective StudiesSeverity of Illness IndexUstekinumabConceptsC-reactive proteinCrohn's diseaseFecal calprotectinInterval shorteningDisease activityStandard doseDose intervalMedian levelsLevels of CRPHarvey-Bradshaw Index scoreUstekinumab dose escalationSubset of patientsEndoscopic remissionClinical remissionEndoscopic evidenceDose escalationSingle centerRetrospective studyPatientsCalprotectinIndex scoreAbstractTextNormal levelsDiseaseWeeks